• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Screening and Treatment Program to Eliminate Hepatitis C in Egypt.

作者信息

Waked Imam, Esmat Gamal, Elsharkawy Aisha, El-Serafy Magdy, Abdel-Razek Wael, Ghalab Reham, Elshishiney Galal, Salah Aysam, Abdel Megid Soad, Kabil Khaled, El-Sayed Manal H, Dabbous Hany, El Shazly Yehia, Abo Sliman Mohamed, Abou Hashem Khalid, Abdel Gawad Sayed, El Nahas Nevine, El Sobky Ahmed, El Sonbaty Sahar, El Tabakh Hamdy, Emad Ehab, Gemeah Hany, Hashem Amal, Hassany Mohamed, Hefnawy Naseif, Hemida Abdel N, Khadary Ayman, Labib Kamal, Mahmoud Faisal, Mamoun Said, Marei Tamer, Mekky Saad, Meshref Alsayeda, Othman Alaa, Ragab Omnia, Ramadan Elhag, Rehan Ahmed, Saad Tarek, Saeed Ramy, Sharshar Mohamed, Shawky Hesham, Shawky Mohamed, Shehata Wael, Soror Hanaa, Taha Mohsen, Talha Mahmoud, Tealaab Adel, Zein Mohamed, Hashish Alaa, Cordie Ahmed, Omar Yasser, Kamal Ehab, Ammar Islam, AbdAlla Mohamed, El Akel Wafaa, Doss Wahid, Zaid Hala

机构信息

From the Hepatology Department, National Liver Institute, Menoufia University, Shebeen El Kom (I.W., W.A.-R.), and the Endemic Medicine Department, Faculty of Medicine, Cairo University (G. Esmat, A.E., M.E.-S., A.C., W.E.A., W.D.), the Ministry of Health and Population (R.G., G. Elshishiney, A.S., S.A.M., M.A.S., K.A.H., S.A.G., N.E.N., A.E.S., S.E.S., H.E.T., E.E., H.G., A. Hashem, N.H., A.N.H., A.K., K.L., F.M., S. Mamoun, T.M., S. Mekky, A.M., A.O., O.R., E.R., A.R., T.S., R.S., M. Sharshar, H. Shawky, M. Shawky, W.S., H. Soror, M. Taha, M. Talha, A.T., M.Z., H.Z.), the National Committee for Control of Viral Hepatitis (K.K.), the Pediatrics Department (M.H.E.-S.), the Hepatology and Tropical Medicine Department (H.D.), and the Department of Medicine (Y.E.S., Y.O.), Ain Shams University, the Hepatology Department, National Hepatology and Tropical Medicine Research Institute (M.H.), the Communicable Diseases Control Cluster, World Health Organization (A. Hashish), the Medical Research Division, National Research Center (E.K., M.A.), and the Tropical Medicine Department, Al-Azhar University (I.A.), Cairo - all in Egypt.

出版信息

N Engl J Med. 2020 Mar 19;382(12):1166-1174. doi: 10.1056/NEJMsr1912628.

DOI:10.1056/NEJMsr1912628
PMID:32187475
Abstract
摘要

相似文献

1
Screening and Treatment Program to Eliminate Hepatitis C in Egypt.埃及消除丙型肝炎的筛查与治疗项目。
N Engl J Med. 2020 Mar 19;382(12):1166-1174. doi: 10.1056/NEJMsr1912628.
2
Association between interleukin 28B polymorphism and sustained virological response to sofosbuvir plus daclatasvir in chronic hepatitis C genotype 4 Egyptian patients.白细胞介素28B基因多态性与4型慢性丙型肝炎埃及患者接受索磷布韦加达卡他韦治疗后的持续病毒学应答之间的关联
J Clin Pharm Ther. 2021 Aug;46(4):942-949. doi: 10.1111/jcpt.13417. Epub 2021 Mar 25.
3
Sofosbuvir Causing Diabetes Mellitus: Is there a Link?索非布韦会引发糖尿病吗?两者有关联吗?
J Coll Physicians Surg Pak. 2018 May;28(5):414. doi: 10.29271/jcpsp.2018.05.414.
4
Sofosbuvir-/Daclatasvir-based therapy for chronic HCV and HCV/hepatitis B virus coinfected patients in Egypt.索磷布韦/达卡他韦方案治疗埃及慢性丙型肝炎及丙型肝炎/乙型肝炎病毒合并感染患者。
Trans R Soc Trop Med Hyg. 2020 Feb 7;114(3):200-212. doi: 10.1093/trstmh/trz079.
5
Leading Role of Sofosbuvir/Daclatasvir in Achieving Hepatitis C Elimination in Egypt.索磷布韦/达卡他韦在埃及实现丙型肝炎消除中的主导作用。
J Viral Hepat. 2025 Jul;32(7):e70032. doi: 10.1111/jvh.70032.
6
MSF pushes down price of generic hepatitis C drugs to new low level.无国界医生组织将通用型丙型肝炎药物价格压低至新的低水平。
BMJ. 2017 Nov 1;359:j5054. doi: 10.1136/bmj.j5054.
7
Evaluation of Glycated Haemoglobin (HbA1c) Level in Type 2 Diabetic Chronic HCV Non-cirrhotic Treatment-Naïve Egyptian Patients Eradicated with Sofosbuvir Plus Daclatasvir.索磷布韦联合达卡他韦治疗初治的2型糖尿病合并慢性丙型肝炎非肝硬化埃及患者糖化血红蛋白(HbA1c)水平的评估
Curr Diabetes Rev. 2020;16(2):165-170. doi: 10.2174/1573399815666190531091128.
8
[Not Available].[无可用内容]
MMW Fortschr Med. 2015 Jun;157 Suppl 2:55. doi: 10.1007/s15006-015-3174-3.
9
Direct-acting antiviral treatment failure in genotype 2 hepatitis C chronic infection.2型丙型肝炎慢性感染中直接抗病毒治疗失败
J Viral Hepat. 2021 Feb;28(2):446-447. doi: 10.1111/jvh.13433. Epub 2020 Nov 18.
10
Response Tailored Protocol Versus the Fixed 12Weeks Course of Dual Sofosbuvir/Daclatasvir Treatment in Egyptian Patients With Chronic Hepatitis C Genotype-4 Infection: A Randomized, Open-label, Non-inferiority Trial.针对埃及慢性丙型肝炎基因型 4 感染患者的应答个体化方案与双索非布韦/达卡他韦固定 12 周疗程的对比:一项随机、开放标签、非劣效性试验。
EBioMedicine. 2017 Jul;21:182-187. doi: 10.1016/j.ebiom.2017.05.011. Epub 2017 May 17.

引用本文的文献

1
Hepatitis C Virus: Epidemiological Challenges and Global Strategies for Elimination.丙型肝炎病毒:流行病学挑战与全球消除策略
Viruses. 2025 Jul 31;17(8):1069. doi: 10.3390/v17081069.
2
Real-World Treatment Efficacy and Safety Profile of Sofosbuvir- and Velpatasvir-Based HCV Treatment in South Korea: Multicenter Prospective Study.索磷布韦和维帕他韦治疗韩国丙型肝炎病毒的真实世界疗效及安全性:多中心前瞻性研究
Viruses. 2025 Jul 4;17(7):949. doi: 10.3390/v17070949.
3
Sensitive RP-HPLC method with fluorimetric detection for concurrent quantification of emtricitabine, Daclatasvir and Ledipasvir in human urine.
采用荧光检测的灵敏反相高效液相色谱法同时定量测定人尿中的恩曲他滨、达卡他韦和雷迪帕韦。
Sci Rep. 2025 Jul 1;15(1):22393. doi: 10.1038/s41598-025-07401-y.
4
Tyrosine kinase inhibitors were well-tolerated among patients with different etiologies of advanced HCC with lower survival in non-viral patients.酪氨酸激酶抑制剂在不同病因的晚期肝癌患者中耐受性良好,非病毒性病因患者的生存率较低。
Sci Rep. 2025 Jun 27;15(1):20323. doi: 10.1038/s41598-025-05828-x.
5
Microelimination of Hepatitis C in Thailand, Phetchabun Model: Progress, Challenges, and Future Directions.泰国碧差汶模式下丙型肝炎的微观消除:进展、挑战与未来方向
J Clin Med. 2025 Jun 3;14(11):3946. doi: 10.3390/jcm14113946.
6
A 2024 global report on national policies, programmes, and progress towards hepatitis C elimination: findings from 33 hepatitis elimination profiles.一份关于丙型肝炎消除的国家政策、计划及进展的2024年全球报告:来自33份肝炎消除概况的调查结果
Lancet Gastroenterol Hepatol. 2025 Jul;10(7):685-700. doi: 10.1016/S2468-1253(25)00068-8. Epub 2025 May 20.
7
Universal HCV Screening in Hospitalised Patients in France: It Could Be a Good Option! The DEVICHO Study.法国住院患者的丙型肝炎病毒通用筛查:这可能是个不错的选择!DEVICHO研究。
J Viral Hepat. 2025 Jun;32(6):e70038. doi: 10.1111/jvh.70038.
8
Autoimmune manifestations and direct-acting antiviral drugs in Egyptian patients with hepatitis C virus infection: A cohort study.埃及丙型肝炎病毒感染患者的自身免疫表现与直接抗病毒药物:一项队列研究。
J Int Med Res. 2025 May;53(5):3000605251339135. doi: 10.1177/03000605251339135. Epub 2025 May 20.
9
Hepatitis C in North Africa: A Comprehensive Review of Epidemiology, Genotypic Diversity, and Hepatocellular Carcinoma.北非的丙型肝炎:流行病学、基因多样性和肝细胞癌的综合综述
Adv Virol. 2025 Mar 24;2025:9927410. doi: 10.1155/av/9927410. eCollection 2025.
10
Global burden and trends of viral hepatitis among women of childbearing age from 1990 to 2021.1990年至2021年育龄妇女中病毒性肝炎的全球负担及趋势
Front Microbiol. 2025 Feb 21;16:1553129. doi: 10.3389/fmicb.2025.1553129. eCollection 2025.